SCHEMBL25720286

SCHEMBL25720286

Cc1cccc(-c2cc(O)n(-c3nc(N4CCOCC4)c4ncccc4n3)n2)c1

nearest known ligand 0.55

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PIK3CA P42336 17/20 0.55
PIK3CD O00329 14/20 0.55
PIK3CG P48736 13/20 0.55
MTOR P42345 10/20 0.55
KDM4E B2RXH2 1/20 0.42
NPC1 O15118 1/20 0.42
ALDH1A1 P00352 1/20 0.42
MAPT P10636 1/20 0.42
HPGD P15428 1/20 0.42
TSHR P16473 1/20 0.42
CASP3 P42574 1/20 0.42
RAB9A P51151 1/20 0.42
KMT2A Q03164 1/20 0.42
SENP8 Q96LD8 1/20 0.42
HSD17B10 Q99714 1/20 0.42
SENP7 Q9BQF6 1/20 0.42
SENP6 Q9GZR1 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30986787 1.00 PIK3CA (0.55) PIK3CAPIK3CDPIK3CGMTORKDM4E
SCHEMBL25270780 0.90 PIK3CA (0.57) PIK3CAPIK3CDPIK3CGMTOR
SCHEMBL30455857 0.84 PIK3CA (0.41) PIK3CAPIK3CDPIK3CGMTORKDM4E
SCHEMBL25225255 0.84 PIK3CA (0.41) PIK3CAPIK3CDPIK3CGMTORKDM4E
SCHEMBL25226288 0.83 GAK (0.44) PIK3CAPIK3CDPIK3CGMTORKDM4E
SCHEMBL25228692 0.82 PIK3CA (0.52) PIK3CAPIK3CDPIK3CGMTORKDM4E
SCHEMBL24470032 0.81 PIK3CA (0.52) PIK3CAPIK3CDPIK3CGMTOR
SCHEMBL24470255 0.79 KDM4E (0.45) PIK3CAMTORKDM4ENPC1ALDH1A1
SCHEMBL25230973 0.74 PIK3CA (0.65) PIK3CAPIK3CDPIK3CGMTOR
SCHEMBL30456439 0.74 PIK3CA (0.65) PIK3CAPIK3CDPIK3CGMTOR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240208964-A1 PYRIDOPYRIMIDINES AND METHODS OF THEIR USE YUMANITY THERAPEUTICS, INC. 2024-06-27 US disclosed
US-20240208964-A1 PYRIDOPYRIMIDINES AND METHODS OF THEIR USE YUMANITY THERAPEUTICS, INC. 2024-06-27 US disclosed
WO-2023107592-A1 PYRIDOPYRIMIDINES AND METHODS OF THEIR USE Kineta, Inc. (US) 2023-06-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240208964-A1 PYRIDOPYRIMIDINES AND METHODS OF THEIR USE PNPO, DPYD, PYGB PIK3CA 3369/4885PIK3CD 3769/4885PIK3CG 3429/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.